Ycanth is a drug owned by Verrica Pharmaceuticals Inc. It is protected by 2 US drug patents filed in 2023 out of which none have expired yet. Ycanth's patents will be open to challenges from 22 July, 2027. Based on its patents and exclusivities, its generic launch date is estimated to be Aug 22, 2038. Details of Ycanth's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11147790 | Treatment of cutaneous disorders |
Aug, 2038
(13 years from now) | Active |
| US11052064 | Compositions, methods and systems for the treatment of cutaneous disorders |
May, 2035
(10 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Ycanth's patents.
Latest Legal Activities on Ycanth's Patents
Given below is the list of recent legal activities going on the following patents of Ycanth.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Second letter to regulating agency to determine regulatory review period | 07 Mar, 2024 | US11052064 |
| Letter from FDA or Dept of Agriculture re PTE application | 07 Feb, 2024 | US11052064 |
| Initial letter Re: PTE Application to regulating agency | 06 Dec, 2023 | US11052064 |
| Patent Term Extension Application under 35 USC 156 Filed | 12 Sep, 2023 | US11052064 |
| Recordation of Patent Grant Mailed Critical | 19 Oct, 2021 | US11147790 |
| Patent Issue Date Used in PTA Calculation Critical | 19 Oct, 2021 | US11147790 |
| Email Notification Critical | 30 Sep, 2021 | US11147790 |
| Issue Notification Mailed Critical | 29 Sep, 2021 | US11147790 |
| Application Is Considered Ready for Issue Critical | 22 Sep, 2021 | US11147790 |
| Dispatch to FDC | 22 Sep, 2021 | US11147790 |
FDA has granted several exclusivities to Ycanth. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Ycanth, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Ycanth.
Exclusivity Information
Ycanth holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Ycanth's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Jul 21, 2028 |
US patents provide insights into the exclusivity only within the United States, but Ycanth is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Ycanth's family patents as well as insights into ongoing legal events on those patents.
Ycanth's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Ycanth's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Aug 22, 2038 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Ycanth Generics:
There are no approved generic versions for Ycanth as of now.
About Ycanth
Ycanth is a drug owned by Verrica Pharmaceuticals Inc. It is used for treating molluscum contagiosum skin lesions in patients 2 years and older. Ycanth uses Cantharidin as an active ingredient. Ycanth was launched by Verrica Pharms in 2023.
Approval Date:
Ycanth was approved by FDA for market use on 21 July, 2023.
NCE-1 date:
NCE-1 date also known as the four year date occurs four years after the original drug approval and marks the first opportunity for a generic manufacturer to file an ANDA with a Paragraph IV certification. This is the earliest point when generic competition might begin, provided the challenge is successful. Since the approval date for Ycanth is 21 July, 2023, its NCE-1 date is estimated to be 22 July, 2027.
Active Ingredient:
Ycanth uses Cantharidin as the active ingredient. Check out other Drugs and Companies using Cantharidin ingredient
Treatment:
Ycanth is used for treating molluscum contagiosum skin lesions in patients 2 years and older.
Dosage:
Ycanth is available in solution form for topical use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.7% | SOLUTION | Prescription | TOPICAL |